{"entity":{"id":"zentalis-pharmaceuticals","kind":"company","name":"Zentalis Pharmaceuticals","aka":[],"tldr":"Zentalis Pharmaceuticals is developing azenosertib, a pill that blocks a cell-cycle checkpoint protein called WEE1, for ovarian cancer that no longer responds to platinum chemotherapy.","summary":"Zentalis Pharmaceuticals is a clinical-stage oncology company whose pipeline is now focused on azenosertib, a potential first-in-class WEE1 inhibitor. The lead indication is Cyclin E1-positive, platinum-resistant ovarian cancer: the DENALI study (parts 2a to 2c) is registration-intent with FDA Fast Track designation, the randomised ASPENOVA trial compares azenosertib with standard chemotherapy, and the MUIR study is testing azenosertib with bevacizumab as maintenance therapy and with chemotherapy backbones. The company states that Cyclin E1 protein overexpression predicts response to azenosertib. Zentalis, which listed on Nasdaq in April 2020 with an IPO raising about 190 million US dollars gross, was based in New York and San Diego at the time and now operates from San Diego.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://zentalis.com/"},{"label":"Pipeline","url":"https://zentalis.com/science/pipeline/"},{"label":"Q1 2020 results noting IPO proceeds (SEC exhibit)","url":"https://www.sec.gov/Archives/edgar/data/1725160/000172516020000006/zentalisq12020earningrel.htm"}],"tags":[],"related":[],"cancers":["ovarian"],"sections":["targeted-therapy"],"technologies":["kinase-inhibitors"],"targets":["wee1"],"drugs":["azenosertib"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Founding year not sourced. Earlier programmes (ZN-c5 oral SERD, ZN-d5 BCL-2) are no longer on the pipeline page."],"hq":"San Diego, CA","country":"US","companyType":"biotech","website":"https://zentalis.com/","ticker":"ZNTL","stage":"public","investors":[],"funding":[{"round":"IPO","year":2020,"amountUsd":190000000,"source":"https://www.sec.gov/Archives/edgar/data/1725160/000172516020000006/zentalisq12020earningrel.htm","note":"10,557,000 shares at 18 US dollars in April 2020; gross proceeds about 190 million US dollars"}]},"route":"/companies/zentalis-pharmaceuticals/","neighbours":{"cancer":[{"id":"ovarian","kind":"cancer","name":"Ovarian cancer","route":"/cancers/ovarian/"}],"section":[{"id":"targeted-therapy","kind":"section","name":"Targeted Therapy","route":"/fronts/targeted-therapy/"}],"technology":[{"id":"kinase-inhibitors","kind":"technology","name":"Small-molecule kinase inhibitors","route":"/technologies/kinase-inhibitors/"}],"target":[{"id":"wee1","kind":"target","name":"WEE1","route":"/targets/wee1/"}],"drug":[{"id":"azenosertib","kind":"drug","name":"Azenosertib","route":"/drugs/azenosertib/"}],"trial":[{"id":"nct07546500","kind":"trial","name":"A Study of Azenosertib (ZN-c3) Versus Investigator's Choice Chemotherapy in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Positive for Cyclin E1 Protein Expression","route":"/trials/nct07546500/"}]}}